logo
Assisted dying bill: Why this momentous vote remains so uncertain

Assisted dying bill: Why this momentous vote remains so uncertain

Independent20-06-2025
The third reading and final Commons vote on Kim Leadbeater's Terminally Ill Adults (End of Life) Bill on Friday marks a truly historic moment for parliament.
The stakes are so high that entrepreneur Declan Ganley has offered a private ambulance to MP Sorcha Eastwood, who is ill with Covid, to get her to the Commons to vote against the Bill.
No wonder. It has been almost six decades since MPs have considered a Bill that would cause such a profound and fundamental change in the state's relationship with individuals and society's attitude to life and death.
An historic vote
In December Ms Leadbeater won a 55 majority on the second reading vote of her Bill, dealing with the principle rather than details, and is expected to carry a reduced majority today, although that is less certain than it was before.
If she is successful then the state, for the first time, will be licensed to end people's lives if they wish it and if the circumstances allow. Doctors will be allowed to offer it as an alternative to people who have been given six months left to live.
What factors will MPs be considering?
The lack of certainty on the vote is partly fueled by the fact that a number of MPs who voted for the principle made it clear that they were allowing the debate to be had and would reserve judgment on the final vote.
The debate in fact has moved on from one of principle - which only a minority oppose - to one of practicalities. The questions faced by MPs include:
Can such a law be introduced to allow those with genuine terminal illnesses who wish to end their lives to do so without exposing the weak, poor and vulnerable to coercion to end their lives?
Can the so-called tight restrictions be prevented from expanding beyond that through medical practice, judicial intervention or further legislation?
Will this end up being a means for saving costs on the care centre and the NHS?
Are the safeguards strong enough to ensure that the new law will not be abused?
What will be the impact on hospices and end of life care?
MPs changing their minds
The reason that the vote has become tighter is because a growing number of MPs are concerned about the potential answers to those questions. The only issue will be whether that is enough to block the Bill.
Based on votes on the amendments as well as known supporters and opponents, the predictive voting model used by opponents of assisted dying gives Ms Leadbeater a majority of up to 15, ranging to a defeat of the Bill by a majority of five. Very close.
Key to the debate will not be the heartbreaking stories of people suffering in their final months, or celebrity voices like Esther Rantzen. They have already had their effect.
More important will be the big change to the Bill brought by Ms Leadbeater which means a judge in court will not have to sign off, as originally laid out in the second reading vote. Instead, there will be an expert panel led by a judge or KC but not with the same legal authority.
It is worth noting that the judicial safeguard was cited by more than 100 MPs in the first debate.
The 'slippery slope' argument
The other issue at play will be whether this Bill is a full stop to the issue or is something that will unleash a loosening up of the law over time.
The lesson from the then Liberal MP David Steel's abortion legislation in 1967 will play a part in the decision-making of a number of MPs, who will be considering the so-called 'slippery slope' issue of an apparently tightly worded piece of legislation expanding its reach over time.
Just this week we have seen MPs vote by a large majority to decriminalise abortion – effectively allowing it up to birth without criminal consequences from the 24 weeks (six months) already legislated for.
But more important will be the experience of other countries where assisted dying has been legalised.
Ms Leadbeater has been at pains that this is a specifically British Bill. However, in Canada, Oregon in the US, the Netherlands, and New South Wales in Australia the legislation has expanded beyond terminal illness to include mental health and other issues.
Ms Leadbeater in fact highlighted a case of a couple who decided to end their own lives in Australia after 70 years of marriage even though terminal illness was not a factor.
How the debate will unfold
She will argue on Friday though that her Bill has been strengthened since November.
Opponents will point out that she has rejected safeguards on eating disorders, mental health, the requirement of people actually suffering pain and many other apparently reasonable checks to the process. Attempts to restrict assisted death advertising were brushed aside. An attempt to protect hospices from offering assisted dying were dismissed.
She had also opposed an amendment preventing doctors recommending assisted dying to children, the one defeat she has suffered so far.
Many have consistently argued that a private members bill is not sufficient to debate something that will have such a profound effect on the country. Indeed, 52 Labour MPs asked Keir Starmer, a supporter of assisted dying, to give more time for further scrutiny, an appeal he rejected.
The issue today will be whether all these questions and issues will mean there are enough MPs to have second thoughts from their vote in November to overturn a 55-majority.
If the Bill is defeated then it will not come back before the next election, if Ms Leadbeater wins then it will have cleared its most important hurdle and a battle in the Lords awaits where many of the issues will be debated again.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Five years after COVID, pharma shares languish in US policy limbo
Five years after COVID, pharma shares languish in US policy limbo

Reuters

time18 minutes ago

  • Reuters

Five years after COVID, pharma shares languish in US policy limbo

MILAN, July 23 (Reuters) - Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the lucrative U.S. market and potential 200% tariffs on pharma imports into the U.S. Money flooded into drugmakers' shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the sector cheap but unloved. At 15.9 times forward earnings, healthcare (.MIWO0HC00PUS), opens new tab trades 11% below its long-term average and 20% below global equities (.MIWO00000PUS), opens new tab, its steepest discount in 16 years, just above a record discount in 2009, based on LSEG Datastream data. "We've moved from cautious optimism to cautious pessimism," said Stephanie Aliaga, global market strategist at J.P. Morgan Asset Management in New York. "Valuations have gotten even cheaper, but for a reason," she added, referring to intensifying U.S. policy risks. But some investors are starting to look past the Washington policy fog and at long-term positive drivers, such as aging populations, RNA-based therapeutics, and breakthroughs in weight-loss and diabetes drugs. Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts boosting this rate-sensitive sector. Interest rate cuts typically support healthcare by lowering R&D funding costs and boosting the value of future cash flows. "These are quality companies with good growth and defensive features being priced as if we're heading into an 'Armageddon scenario', which I believe is unlikely," he said. UK-based M&G Investments has also been selectively adding to healthcare, according to its latest allocation report. Healthcare funds have seen net inflows since 2024, more than reversing the outflows from late 2022 through 2023, fund tracker EPFR data shows. Although year-to-date, inflows total $7.2 billion, down 41% from last year. Innovation is accelerating, pipelines are maturing and M&A is showing signs of picking up - yet stock prices are unmoved. Whether that represents a buying opportunity or a value trap hinges on how and when the policy uncertainty clears, investors said. Historically, healthcare has traded at a modest premium to world stocks, thanks to its defensive profile and steady earnings. But that narrative has unravelled under political pressure from Washington and investors' love of Big Tech. Over the past three years, U.S. healthcare (.SPXHC), opens new tab has underperformed the S&P 500 (.SPX), opens new tab by more than 60 percentage points, making it the worst sectoral performer on Wall Street. Its valuation has deepened to a near-record 27% discount, from parity to the S&P in 2023. "Markets don't like uncertainty, and that shows up in valuations," said Eddie Yoon, healthcare sector leader and portfolio manager at Fidelity Investments in Boston. "Being cheap isn't necessarily a reason to buy. You need a catalyst." For now, that catalyst is elusive. The policy uncertainty makes it difficult to forecast future earnings, he said, though he hopes for more clarity by year-end - potentially also paving the way for more M&A in the industry. Talks with the Trump administration have yet to clarify how and when drug prices will fall, executives from Eli Lilly (LLY.N), opens new tab and Merck (MRK.N), opens new tab said at a May industry conference. Yoon, who has typically been underweight Big Pharma due to patent expiry risks, notes smaller, innovative firms are becoming profitable. "We're seeing companies go from unprofitable to very profitable," he said, citing Alnylam (ALNY.O), opens new tab and Penumbra (PEN.N), opens new tab as examples he owns. "Historically, that's been a very good time to own healthcare stocks." LFG+ZEST's Conca, who favours U.S. names like Abbott (ABT.N), opens new tab, Edwards Lifesciences (EW.N), opens new tab, and AbbVie (ABBV.N), opens new tab, along with Sanofi ( opens new tab and Recordati ( opens new tab in Europe, said interest rate cuts could be a major catalyst. In Europe, healthcare (.SXDP), opens new tab is even cheaper than U.S. pharma, trading at 14.3 times forward earnings. A 55% drop in shares of Novo Nordisk ( opens new tab in the last year, related in part to concerns over competition in obesity drugs, along with tariff-driven production shifts to the U.S., has weighed on valuations. "The sector will adapt," wrote Arnaud Cadart, healthcare analyst at France's CIC Market Solutions. But that will come "at the cost of rebalancing its revenues and probably transforming its organisations." AstraZeneca (AZN.L), opens new tab, for example, has unveiled a $50 billion U.S. investment. For now, the sector remains in limbo: cheap, but lacking enough visibility to trigger a broad re-rating. "Healthcare has endured a lot of pain," said J.P. Morgan's Aliaga. "We're not sure if that pain is done, but the worst is likely over, given how extreme the exodus has been."

Rayner criticised over summer riots warning
Rayner criticised over summer riots warning

The Independent

time19 minutes ago

  • The Independent

Rayner criticised over summer riots warning

Michael Gove has criticised Deputy Prime Minister Angela Rayner 's warnings about potential summer violence, stating they could "tacitly encourage" riots and were a "big mistake". Ms Rayner on Tuesday warned cabinet colleagues about rising community tensions, linking them to economic difficulties, immigration, and declining living standards, following violent incidents in Epping. Mr Gove, a former Tory communities secretary, argued that predicting such violence makes it seem inevitable and portrays the government as being "at the mercy of events". He also cautioned against anticipating or encouraging violence. Conservative leader Kemi Badenoch said she does not expect another summer of riots but highlighted the need for vigilance, blaming Labour for strains on social cohesion.

Essex Police say counter-protester transport claims ‘categorically wrong'
Essex Police say counter-protester transport claims ‘categorically wrong'

The Independent

time19 minutes ago

  • The Independent

Essex Police say counter-protester transport claims ‘categorically wrong'

Essex Police have denied claims officers 'bussed' counter-demonstrators to a protest outside a hotel housing asylum seekers last week, calling them 'categorically wrong'. A series of demonstrations has taken place outside the Bell Hotel in Epping since asylum seeker Hadush Gerberslasie Kebatu, 38, was charged with sexual assault after an incident earlier this month, in which he is alleged to have attempted to kiss a 14-year-old girl. The force said the protests began peacefully but 'escalated to the point of disorder and criminal damage', with eight officers injured at one demonstration outside the hotel on Thursday evening and five men charged with disorder at the protests. Claims around the deliberate use of counter-demonstrators being taken to the protests led to Reform UK leader Nigel Farage calling for Essex Police's chief constable to resign on Wednesday. Alongside footage shared in a post on X, the Clacton MP said: 'This video proves @EssexPoliceUK transported left-wing protesters to the Bell Hotel in Epping. There is no way Chief Constable BJ Harrington can stay in position.' But in a statement released shortly afterwards, a force spokesperson said: 'There are claims on social media that Essex Police officers 'bussed' protesters to the protest outside the Bell Hotel on Thursday July 17. 'This is categorically wrong. 'Officers did provide a foot cordon around protesters on their way to the protest, where they and others were allowed to exercise their right to protest. 'Later, some people who were clearly at risk of being hurt were also escorted by vehicle away from the area for their safety. 'To reiterate, we categorically did not drive any counter-protesters to the site on any occasion.' In an update to the gathered media in Chelmsford, Chief Constable Ben-Julian Harrington said Essex Police had made 10 arrests following the protests. He said: 'I want to thank the people of Epping, I want to thank the people of Essex. 'I also want to thank all those who have turned up to protest and express their views peacefully and lawfully, because there have been many of those. 'What has been unacceptable has been the people who have come to Epping and committed violence, who have attacked people who work at the hotel, who have attacked officers, who have damaged property and who have caused fear and disruption to the people of Epping.' Mr Harrington said the force were aware of 'a couple' of protests being advertised and discussed over the coming week, and that it had a robust operation in place. 'It's abOut communities. It's about protecting communities, whoever they are,' he added. Kebatu denied the sexual assault charge when he appeared at Chelmsford Magistrates' Court on Thursday. Jonathan Glover, 47, of Springfields, Waltham Abbey, Stuart Williams, 36, of Duck Lane, Thornwood, Epping, Keith Silk, 33, of Torrington Drive, Loughton, and Dean Smith, 51, of Madells, Epping, have been charged with violent disorder in connection with the protests and are due to appear at the same court on August 18, Essex Police said on Tuesday. A fifth man, Joe McKenna, 34, of Highcliffe Road, Wickford, is charged with failing to remove a face covering when told to do so and remains on bail until a hearing at Chelmsford Magistrates' Court on September 24. Essex Police previously said the cost of policing the incidents in Epping over the last week had reached £100,000.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store